Who is sponsoring NCT00101907?

NCT00101907 is sponsored by Amgen.

What condition does NCT00101907 study?

NCT00101907 studies Lung Cancer, Pancreatic Cancer, Esophageal Cancer.

What drugs are being tested in NCT00101907?

Interventions: AMG 706, Panitumumab, Gemcitabine, Cisplatin.

What is the status of NCT00101907?

NCT00101907 is currently TERMINATED.

Last reviewed 2014-02-03 · How we verify

An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer

NCT00101907 Phase 1 TERMINATED Results posted

The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with gemcitabine and cisplatin chemotherapy. This is a Phase 1b clinical study.

Details

Lead sponsor	Amgen
Phase	Phase 1
Status	TERMINATED
Enrolment	41
Start date	2004-12
Completion	2008-04

Conditions

Lung Cancer
Pancreatic Cancer
Esophageal Cancer

Interventions

AMG 706
Panitumumab
Gemcitabine
Cisplatin

Primary outcomes

Participant Incidence of Adverse Events — From the first dose of any study treatment until 30 days after the last dose of study treatment, up to a maximum of 509 days.
The number of participants who experienced at least one treatment-emergent adverse event. Additional details regarding specfic adverse events are provided in the Adverse Event section of this posting.